SAGE Therapeutics Inc. (SAGE)

162.00
NASDAQ : Health Technology
Prev Close 161.03
Day Low/High 159.49 / 163.62
52 Wk Low/High 79.88 / 193.56
Avg Volume 373.30K
Exchange NASDAQ
Shares Outstanding 51.65M
Market Cap 8.32B
EPS -8.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Sage Receives FDA Breakthrough Therapy Designation For SAGE-547 For The Treatment Of Postpartum Depression

Sage Receives FDA Breakthrough Therapy Designation For SAGE-547 For The Treatment Of Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.

Sage Therapeutics And Collaborators Announce Publication Highlighting Epidemiology And Burden Of Illness For Super-Refractory Status Epilepticus In Journal Of Medical Economics

Sage Therapeutics And Collaborators Announce Publication Highlighting Epidemiology And Burden Of Illness For Super-Refractory Status Epilepticus In Journal Of Medical Economics

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the publication of a study conducted...

Short Interest In Sage Therapeutics Expands By 12.7%

Short Interest In Sage Therapeutics Expands By 12.7%

The most recent short interest data has been released for the 07/29/2016 settlement date, which shows a 463,924 share increase in total short interest for Sage Therapeutics Inc , to 4,131,029, an increase of 12.65% since 07/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

SAGE Therapeutics (SAGE) Stock Closes Sharply Lower on 2Q Loss

SAGE Therapeutics (SAGE) Stock Closes Sharply Lower on 2Q Loss

SAGE Therapeutics (SAGE) reported wider losses for the second quarter before today's opening bell.

Sage Therapeutics Announces Second Quarter 2016 Financial Results And Provides Corporate Update

Sage Therapeutics Announces Second Quarter 2016 Financial Results And Provides Corporate Update

Sage Therapeutics, Inc. (NASDAQ: SAGE) today reported business highlights and financial results for the second quarter ended June 30, 2016, and provided an update on corporate strategy and financial guidance.

Sage Therapeutics To Present At The Canaccord Genuity 36th Annual Growth Conference

Sage Therapeutics To Present At The Canaccord Genuity 36th Annual Growth Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.

Sage Therapeutics To Report Second Quarter 2016 Financial Results On Tuesday, August 9, 2016

Sage Therapeutics To Report Second Quarter 2016 Financial Results On Tuesday, August 9, 2016

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a...

Biogen Should Either a Buyer or a Seller Be

Biogen Should Either a Buyer or a Seller Be

The company sans CEO Scangos needs to do some type of deal in the coming months.

Sage Appoints Geno Germano To Company's Board Of Directors

Sage Appoints Geno Germano To Company's Board Of Directors

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, announced today that Geno Germano has been appointed to Sage's...

Sage Therapeutics (SAGE) CEO Jonas Tells CNBC He's 'Very Excited' By Positive Drug Results

Sage Therapeutics (SAGE) CEO Jonas Tells CNBC He's 'Very Excited' By Positive Drug Results

Sage Therapeutics (SAGE) CEO Jeff Jonas told CNBC that the positive study results of the company's drug to treat postpartum depression are 'remarkable.'

SAGE Shares Surge After Postpartum Depression Drug Shows Promise

SAGE Shares Surge After Postpartum Depression Drug Shows Promise

Shares of SAGE Therapeutics jumped after the company reported data from its SAGE-547 clinical trial for the treatment of severe postpartum depression.

Jim Cramer -- Sage Therapeutics Posts 'Remarkable Results'

Jim Cramer -- Sage Therapeutics Posts 'Remarkable Results'

Cramer says the drug could be huge but be alert for the stock rallying too far too fast.

Sage Therapeutics Drug Eliminates Postpartum Depression in Mid-Stage Trial

Sage Therapeutics Drug Eliminates Postpartum Depression in Mid-Stage Trial

The trial found 70% of women with postpartum depression treated with SAGE-547 achieved no more depression after 60 hours compared to just under 10% of women treated with placebo.

Sage Reports Positive Top-line Results Including Demonstration Of 30-Day Durability From Phase 2 Clinical Trial Of SAGE-547 In Severe Postpartum Depression

Sage Reports Positive Top-line Results Including Demonstration Of 30-Day Durability From Phase 2 Clinical Trial Of SAGE-547 In Severe Postpartum Depression

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced positive top-line results from its Phase 2...

A Biotech Stock Turnaround Requires an Alzheimer's Drug Miracle

A Biotech Stock Turnaround Requires an Alzheimer's Drug Miracle

What if the only sentiment-turning catalyst left for biotech stocks this year is the outcome of Eli Lilly's Alzheimer's phase III study expected around Christmas?

First Week of SAGE February 2017 Options Trading

First Week of SAGE February 2017 Options Trading

Investors in Sage Therapeutics Inc saw new options become available this week, for the February 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Sage Therapeutics' Approach To GABA Receptor Drug Development

Sage Therapeutics' Approach To GABA Receptor Drug Development

Sage Therapeutics (NASDAQ:SAGE) today announced positive top-line results from its Phase 1 clinical program of SAGE-217, a novel, internally-developed orally active compound intended to enhance GABA receptor mediated...

Sage Therapeutics To Present At The Goldman Sachs 37th Annual Global Healthcare Conference

Sage Therapeutics To Present At The Goldman Sachs 37th Annual Global Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.

Biotech Stock Mailbag: Sage Therapeutics, Minerva

Biotech Stock Mailbag: Sage Therapeutics, Minerva

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Sage Therapeutics Announces Completion Of Enrollment For Phase 2 Proof-of-Concept Trial Of SAGE-547 In Severe Postpartum Depression

Sage Therapeutics Announces Completion Of Enrollment For Phase 2 Proof-of-Concept Trial Of SAGE-547 In Severe Postpartum Depression

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that enrollment has been...

First Week of SAGE July 15th Options Trading

First Week of SAGE July 15th Options Trading

Investors in Sage Therapeutics Inc saw new options become available this week, for the July 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SAGE options chain for the new July 15th contracts and identified one put and one call contract of particular interest.

Monsanto, Amazon and Apple: Doug Kass' Views

Monsanto, Amazon and Apple: Doug Kass' Views

Doug Kass shares his thoughts on shorting financials, and wonders if it will be a Monsanto merger Monday.

Sage Therapeutics Announces First Quarter 2016 Financial Results

Sage Therapeutics Announces First Quarter 2016 Financial Results

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and...

Sage Therapeutics To Report First Quarter 2016 Financial Results On Thursday, May 5, 2016

Sage Therapeutics To Report First Quarter 2016 Financial Results On Thursday, May 5, 2016

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a...

Sage Therapeutics Expands Scientific, Clinical And Burden Of Illness Data For SAGE-547 In SRSE And Essential Tremor At The 2016 American Academy Of Neurology Annual Meeting

Sage Therapeutics Expands Scientific, Clinical And Burden Of Illness Data For SAGE-547 In SRSE And Essential Tremor At The 2016 American Academy Of Neurology Annual Meeting

Sage Therapeutics, Inc. (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced data from five abstracts to be...

Facebook, Ford and General Motors: Doug Kass' Views

Facebook, Ford and General Motors: Doug Kass' Views

Doug Kass shares his thoughts on two auto stocks and Facebook.

First Week of SAGE November 18th Options Trading

First Week of SAGE November 18th Options Trading

Investors in Sage Therapeutics Inc saw new options become available this week, for the November 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Sage Therapeutics, Inc. - SAGE

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Sage Therapeutics, Inc. - SAGE

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Sage Therapeutics, Inc.

Here’s Why Sage Therapeutics (SAGE) Stock is Tumbling Today

Here’s Why Sage Therapeutics (SAGE) Stock is Tumbling Today

Sage Therapeutics (SAGE) stock is plunging on Wednesday after Kerrisdale Capital said it had shorted the stock and that its experimental drug would likely fail an important late stage study.